1) Tefferi A:Polycythemia vera and essential thrombocythemia:2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:284-93 2) Tefferi A, Vannucchi AM, Barbui T:Polycythemia vera treatment algorithm 2018. Blood Cancer J 2018;8(１):3 3) Marchioli R, Finazzi G, Specchia G, et al, CYTO-PV Collaborative Group:Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33 4) Marchioli R, Vannucchi AM, Barbui T:Treatment target in polycythemia vera. N Engl J Med 2013;368:1556 5) Liu H, Liu H, Shen J, et al:A clinical analysis of erythrocytapheresis for the treatment of polycythemia. Transfus Apher Sci 2013;48:229-33 6) Evers D, Kerkhoffs JL, Van Egmond L, et al:The efficiency of therapeutic erythrocytapheresis compared to phlebotomy:a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis. J Clin Apher 2013;29(３):133-8 7) Vecchio S, Leonardo P, Musuraca V, et al:A comparison of the results obtained with traditional phlebotomy and with therapeutic erythrocytapheresis in patients with erythrocytosis. Blood Transfus 2007;5:20-3 8) Kaboth U, Rumpf KW, Liersch T, et al:Advantages of isovolemic large-volume erythrocytapheresis as a rapidly effective and long-lasting treatment modality for red blood cell depletion in patients with polycythemia vera. Ther Apher 1997;1:131-4
